Clinical Trial Update: Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating brachytherapy in combination with durvalumab or tremelimumab for platinum-resistant, refractory, recurrent, or metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING